Daily Stock Analysis, BSTC, Biospecifics Technologies Corp, priceseries

Biospecifics Technologies Corp. Daily Stock Analysis
Stock Information
Open
59.23
Close
59.96
High
60.69
Low
59.23
Previous Close
59.23
Daily Price Gain
0.73
YTD High
73.31
YTD High Date
Feb 19, 2019
YTD Low
45.81
YTD Low Date
Oct 24, 2019
YTD Price Change
-0.03
YTD Gain
-0.05%
52 Week High
73.31
52 Week High Date
Feb 19, 2019
52 Week Low
45.81
52 Week Low Date
Oct 24, 2019
52 Week Price Change
-0.04
52 Week Gain
-0.07%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 8. 2018
46.66
Aug 23. 2018
51.01
11 Trading Days
9.33%
Link
Company Information
Stock Symbol
BSTC
Exchange
NasdaqGM
Company URL
http://www.biospecifics.com
Company Phone
5165937000
CEO
Thomas L. Wegman
Headquarters
New York
Business Address
35 WILBUR ST, LYNBROOK, NY 11563
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000875622
About

BioSpecifics Technologies Corp. operates as a biopharmaceutical company, which engages in development of an injectable collagenase for multiple indications. Its product includes XIAFLEX, is an injectable collagenase enzyme, which is used for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm. The company was founded in 1990 and is headquartered in Lynbrook, NY.

Description

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.